The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2025 | Approaching treatment for patients with newly diagnosed transplant-ineligible multiple myeloma
Sosana Delimpasi, MD, General Hospital Evangelismos, Athens, Greece, discusses her approach to treatment for patients with newly diagnosed transplant-ineligible multiple myeloma. Dr Delimpasi highlights the use of combination therapies, as well as CAR T-cells. This interview took place at the 30th Congress of the European Hematology Association (EHA) in Milan, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Transplant ineligible patients, depending on their status and their age, is a difficult to reach population because you must balance between safety and of course efficacy. Nowadays, with the new ASH guidelines, this patient, the first line treatment, must consist of an IMiD that is lenalidomide and also an anti-CD38 antibody that usually is daratumumab because it is subcutaneous...
Transplant ineligible patients, depending on their status and their age, is a difficult to reach population because you must balance between safety and of course efficacy. Nowadays, with the new ASH guidelines, this patient, the first line treatment, must consist of an IMiD that is lenalidomide and also an anti-CD38 antibody that usually is daratumumab because it is subcutaneous. But with the new results from the Cepheus trial, the new therapeutic lines in a group of patients that can tolerate and these are usually patients below the age of 80. One could also propose to give Velcade together. This combination has the probability to give patients a 10-year progression-free survival, which is very important but eventually many patients will also relapse and so I believe the combination of selinexor with Velcade in this population especially with those reductions is very effective and one can think that this could be a combination that is very good and if the patient doesn’t respond to this or progresses again then there are of course other treatments like CARs and other things that are also suitable for patients that are transplant eligible but they must be fitter.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
